Compare Newmont Corporation (NEM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Newmont Corporation trades at $92.38 (market cap $95.23B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Newmont Corporation is far larger — about 62.2× Recursion Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 1.17% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NEM | RXRX | |
|---|---|---|
Market Cap | $95.23B | $1.53B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $6.79 |
52-Week Low | $59.86 | $2.84 |
Enterprise Value | $91.98B | $946.50M |
Dividend Yield | 1.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
